We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.95B
AUM Growth
-$1.05B
Cap. Flow
+$64.3M
Cap. Flow %
1.08%
Top 10 Hldgs %
34.22%
Holding
172
New
36
Increased
33
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$126M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$126M
3
PASG icon
Passage Bio
PASG
+$109M
4
PFE icon
Pfizer
PFE
+$108M
5
CNC icon
Centene
CNC
+$81M

Top Sells

Rank Stock Value
1
THOR
Synthorx, Inc. Common Stock
THOR
+$372M
2
ARQL
Arqule Inc
ARQL
+$99.8M
3
DHR icon
Danaher
DHR
+$98.1M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$79.2M
5
INSP icon
Inspire Medical Systems
INSP
+$74M

Sector Composition

Rank Sector Weight
1 Healthcare 96.88%
2 Financials 1.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRC icon
51
AtriCure
ATRC
$2.01B
$31.2M 0.52%
928,189
+759,568
+450% +$27.3M
PRTA icon
52
Prothena Corp
PRTA
$444M
$31.1M 0.52%
2,902,239
– –
ATNX
53
DELISTED
Athenex, Inc. Common Stock
ATNX
$31M 0.52%
200,467
+61,856
+45% +$15.6M
CRNX icon
54
Crinetics Pharmaceuticals
CRNX
$8.87B
$30M 0.5%
2,039,282
– –
NSTG
55
DELISTED
NanoString Technologies, Inc.
NSTG
$28.7M 0.48%
+1,192,400
New +$34.5M
HARP
56
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$28.3M 0.48%
244,641
– –
ACHC icon
57
Acadia Healthcare
ACHC
$2.62B
$25.3M 0.43%
+1,380,160
New +$39.5M
SCPH
58
DELISTED
scPharmaceuticals
SCPH
$25.2M 0.42%
3,409,865
– –
TELA icon
59
TELA Bio
TELA
$30.4M
$23.7M 0.4%
3,027,542
– –
CRSP icon
60
CRISPR Therapeutics
CRSP
$4.64B
$23.4M 0.39%
551,200
-215,178
-28% -$11.1M
XLRN
61
DELISTED
Acceleron Pharma
XLRN
$23.1M 0.39%
257,549
+150,049
+140% +$11.7M
BFYT
62
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
$21.6M 0.36%
+962,900
New +$22.9M
AMGN icon
63
Amgen
AMGN
$213B
$21.3M 0.36%
105,200
-16,900
-14% -$3.69M
INSP icon
64
Inspire Medical Systems
INSP
$1.49B
$20.9M 0.35%
347,000
-1,000,000
-74% -$74M
ZYME icon
65
Zymeworks
ZYME
$1.63B
$20.7M 0.35%
+582,302
New +$23.8M
NVO
66
Novo Nordisk
NVO
$227B
$19.9M 0.33%
660,000
– –
AUPH icon
67
Aurinia Pharmaceuticals
AUPH
$1.92B
$19.4M 0.33%
1,336,547
-1,008,900
-43% -$17.8M
IQV icon
68
IQVIA
IQV
$41.1B
$18.9M 0.32%
175,000
– –
XENE icon
69
Xenon Pharmaceuticals
XENE
$6.24B
$18.9M 0.32%
1,662,812
+1,028,000
+162% +$14.6M
ALC icon
70
Alcon
ALC
$34B
$17.9M 0.3%
351,380
– –
ABBV icon
71
AbbVie
ABBV
$469B
$17.4M 0.29%
+229,000
New +$19.5M
SVA
72
DELISTED
Sinovac Biotech, Ltd
SVA
$17.2M 0.29%
2,839,500
– –
SIBN icon
73
SI-BONE Inc
SIBN
$799M
$16.5M 0.28%
+1,381,300
New +$25.4M
PFE icon
74
CALL
Pfizer
PFE
$144B
$16.3M 0.27%
+527,000
New +$18M
PHGE icon
75
BiomX
PHGE
$1.95M
$16.2M 0.27%
12,176
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2020 Portfolio in Review

As of Q1 2020, OrbiMed held 172 positions worth $5.95B, down 15% from $7B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2020 filing shows 36 new, 33 increased, 28 reduced and 30 closed positions. Its largest new stake was Arcutis Biotherapeutics: 4,673,850 shares worth $139M. The largest sale was Synthorx, Inc. Common Stock, an estimated $372M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q1 2020 buy was Arcutis Biotherapeutics: 4,673,850 shares worth $139M.
  • OrbiMed added most to Biogen in Q1 2020, an estimated $126M increase.
  • OrbiMed's biggest Q1 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $79.2M.
  • OrbiMed fully exited Synthorx, Inc. Common Stock in Q1 2020, selling an estimated $372M.
  • OrbiMed's ten largest holdings make up 34% of its $5.95B portfolio in Q1 2020.
  • OrbiMed opened 36 new positions and closed 30 in Q1 2020.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $5.95B.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.